Klinicheskie i patofiziologicheskie osobennosti anemii pri diabeticheskoy nefropatii
https://doi.org/10.14341/2072-0351-5753
Abstract
Цель. Изучение распространенности, клинических и патофизиологических особенностей анемии у больных ДН. Материалы и методы. Для изучения распространенности анемии обследовали 1020 человек ? 382 больных СД 1 и 638 больных СД 2. Оценивали СКФ, выявляли анемию. Сравнительный анализ частоты выявления анемии при диабетическом и недиабетическом поражении почек проводили между 92 больными с протеинурической стадией ДН при СД 1 и 230 больными с морфологически подтвержденным диагнозом первичного хронического гломерулонефрита (ХГН). Результаты. По данным нашего исследования, в популяции больных ДН связь уровня Hb крови и ЭПО отсутствовала уже при снижении СКФ менее 60 мл/мин. Более чем 80% больных ДН и с анемией наблюдалось нарушение обмена железа. Заключение. при ДН анемия выявляется намного чаще, чем при других заболеваниях почек ? частота ее составляет до 25% при нормальной СКФ и достигает до 80?100% при выраженной степени снижения фильтрационной функции почек. На самой ранней стадии ДН ? МАУ ? анемия встречается практически у каждого четвертого, а при формировании ПУ ? уже у каждого второго больного. Анемия при ДН носит более тяжелый характер, чем при первичном нефрите.
References
1. Thomas M., MacIsaac J., Tsalamandris C., Molyneaux L. et al. Anemia in patients with type 1 diabetes. The Journal of Clinical Endocrinology and Metabolism 2004; 89 (9): 4359-4363.
2. Thomas M., MacIsaac J., Tsalamandris C., Molyneaux L. et al. The burden of anemia in type 2 diabetes and role of nephropathy: a cross-sectional audit. Nephrology Dialysis Transplantation 2004; Vol.19: 1792- 1797.
3. Thomas M., MacIsaac R.J., Power D., Jerums G. Unrecognized anemia in patients with diabetes. Diabetes Care 2003; 26 (4): 1164-1169.
4. Broon J. Anemia in diabetic renal disease: and underestimated risk factor. Acta Diabetologica 2002; 39: S2.
5. Stevens P.E., O'Donoghue j., Lameire N.R. Anemia in patients with diabetes: unrecognized, undetected and untreated? Current Medical Research and Opinion 2003; 19 (5): 395-401.
6. Mohanram A., Zhang Z., Shaninfar S. et al. Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy. Kidney International 2004; 66: 1131-1138.
7. Thomas M. Anemia in diabetes: marker o mediator of microvascular disease. Nature Clinical Practice Nephrology 2007; 1 (3): 20-30.
8. Cockroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
9. El-Achkar T.M., Ohmit S.E., McCullough P.A. et al. Higher prevalence of anemia with diabetes mellitus in moderate kidney insufficiency: The Kidney Early Evaluation Program. Kidney International 2005; 67: 1483-1488.
10. Astor B.C., Muntner P., Levin A. et al. Association of kidney function with anemia: The Third National Health and Nutrition Examination Survey (1988-1994). Archives of Internal Medicine 2002; 162: 1401-1408. 14. World Health Organization. Iron Deficiency Anaemia, Assessment, Prevention and Control: a guide for programme managers. 2001.
11. King H., Aubert R.E., Herman W.H. Global burden of diabetes, 1995- 2025: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21: 1414-1431.
12. Шестакова М.В., Мартынов С.А. Анемия при диабетической нефропатии: прогностическое значение, диагностика и лечение. Consilium medicum 2006; 9: 39-43.
13. Шестакова М.В., Мартынов С.А. Диабетическая нефропатия: все ли факторы риска мы учитываем? Сахарный диабет 2006; 4: 29-33.
14. Шестакова М.В., Мартынов С.А. Анемия при диабетической нефропатии: диагностика и лечение. М: 2007.
15. White K.E., Marshall S.M., Bilous W. Are glomerular volume differences between type 1 and type 2 diabetic patients pathologically significant? Diabetologia 2007; 50 (5): 906-912.
16. Thomas M.C., Tsalamandris C., MacIsaac R.J., Jerums G. Epidemiology of hemoglobin levels in patients with type 2 diabetes. American Journal of Kidney Diseases 2006; 48: 537-545.
17. Thomas M.C., Weekes A.J., Broadley O.J. et al. The burden chronic kidney disease in Australian patients with type 2 diabetes (the Nephron study). The Medical Journal of Australia 2006; 185: 140-144.
18. Lorber D., Reddan D. Clinical characteristics of chronic kidney disease patients with and without diabetes: a subanalysis of the PAERI study. Clinical Nephrology 2006; 66: 11-16.
19. Ishimura E., Nishizawa Y., Okuto S. et al. Diabetes mellitus increases the severity of anemia in non-dialyzed patients with renal failure. Journal of Nephrology 1998; 11: 83-86.
20. Румянцев А.Г., Морщакова Е.Ф., Павлов А.Д. Эритропоэтин в диагностике, профилактике и лечении анемий. М: 2003.
21. Ермоленко В.М., Иващенко М.А. Уремия и эритропоэтин. М: 2000.
22. Zhu H., Jackson T., Bunn H.F. Detecting and responding to hypoxia. Nephrology Dialysis Transplantation 2002, 17 [Suppl. 1]: 3-7.
23. Maxwell P. HIF-1: An Oxygen Response System with Special Relevance to the Kidney. Journal of the American Society of Nephrology 2003; 14: 2717-2722. Сахарный диабет Нефрология 22 2/2008
24. Artunc F., Risler A. Serum erythropoietin concentrations and responses to anemia in patients with or without chronic kidney disease. Nephrology Dialysis Transplantation 2007; 22: 2900-2908.
25. Bosman D.R., Winkler A.S., Marsden J.T. et al. Anemia with erythropoietin deficiency occurs early in diabetic nephropathy. Diabetes Care 2001; 24 (3): 495-499.
26. Fehr T., Ammann P., Garzoni D. et al. Interpretation of erythropoietin levels in patients with various degrees of renal insufficiency and anemia, Kidney International 2004; 66: 1206-1244.
27. Rossert J., Fouqueray B., Boffa J.J. Anemia management and the delay of chronic renal failure progression. Journal of the American Society of Nephrology 2003; 14: S173-177.
28. White K.E., Bilous R.W. Type 2 diabetic patients with nephropathy show structural functional relationships that are similar type 1 disease. Journal of the American Society of Nephrology 2000; 11:1667-1673.
29. Fitzgibbons J.F., Roler R.D., Jones R. Red cell age-related changes of hemoglobin AIa+b and AIc in normal and diabetic subjects. The Journal of Clinical Investigation 1972; 58: 820-824.
30. Nakao T., Matsumoto H., Okada T. et al. Influence of erythropoietin treatment on hemoglobin A1c levels in patients with chronic renal failure on heamodialysis. Internal Medicine 1998; 37: 826-830.
31. Шестакова М.В., Лепетухин А.Е., Кварацхелия М.В., Дедов И.И. Особенности ведения больных сахарным диабетом с терминальной почечной недостаточностью на программной гемодиализе. Терапевтический архив 2004; 9:2004, с-70-75.
32. Bosman D.R., Osborne C.A., Marsden J.T. et al. Erythropoietin response to hypoxia in patients with diabetic autonomic neuropathy and non-diabetic chronic renal failure. Diabetic Medicine 2002; 19:65-69.
33. MacDougall I.C., Cooper A. The inflammatory response and epoetin sensitivity. Nephrology Dialysis Transplantation 2002; 17 [Suppl. 1]: 48-52.
34. Stenvinkel P. Anemia and inflammation: what are the implications for the nephrologist? Nephrology Dialysis Transplantation 2003; 18 [Suppl. 8]: viii17-viii22.
35. Stenvinkel P., Barany P. Anemia, rHuEPO resistance, and cardiovascular disease in end stage renal failure: links to inflammation and oxidative stress. Nephrology Dialysis Transplantation 2002; 17 [Suppl. 5] 32-37.
36. Weiss G., Goodnough L. Anemia of chronic disease. The New England journal of medicine 2005; 352: 1011-1023.
37. Zou A.P., Cowley A.W. Reactive oxygen species and molecular regulation of renal oxygenation. Acta Phisiologica Scandinavica 2003; 179: 233-241.
38. Cavdar C., Camsari T., Semin I. et al. Lipid peroxidation and antioxidant activity in chronic haemodialysis patients treated with recombinant human erythropoietin. Scandinavian Journal of Urology and Nephrology 1997; 31:371-375.
39. Ludat K., Sommerburg O., Grune T. et al. Oxidation parameters in complete correction of renal anemia. Clinical Nephrology 2000; 53:S30- S35.
40. Dikow R., Schwenger V., Schцmig M., Ritz E. How should we manage anemia in patients with diabetes? Nephrology Dialysis Transplantation 2002; 17 [Suppl 1]: 67-72.
41. MacDougall I. The role of ACE inhibitor and angiotensin II receptor blockers in the response to epoetin. Nephrology Dialysis Transplantation 1999; 14:1836-1841.
42. Pratt M.C., Lewis-Barnard N.J., Walker R.J. et al. Effect of angiotensin converting enzyme inhibitors on erythropoietin concentration in healthy volunteers. British Journal of Clinical Pharmacology 1992; 34: 363-365.
43. Stevens P. Optimizing renal anemia management - benefits of early referral and treatment. Nephrology Dialysis Transplantation 2005; 20 [Suppl. 8]: viii22-viii26.
44. National Kidney Foundation: K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation Classification and Stratification. American Journal of Kidney Diseases 2002; 39 [Supl 1]: S1-S266.
45. World health organization. Nutritional Anemia: Report of WHO Scientific Group. World Health Organization. Geneva; 1968.
46. National Kidney Foundation: K/DOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia of chronic kidney disease American Journal of Kidney Diseases 2006; 47 [Supl 3]: S1-S145.
47. USRDS 2007 Annual Data Report, volume i. Atlas of chronic kidney disease and end-stage renal disease in United States. http://www.usrds.org/
48. Catrina S-B., Okamoto K., Pereira T. et al. Hyperglycemia regulates hypoxia-inducible factor-1α protein stability and function. Diabetes 2004; 53: 3226-3232.
49. Locatelli F, Aljama P, Barany P. et al. Revised European best practice guidelines for the management of anemia in patients with chronic renal failure. Nephrology Dialysis Transplantation 2004; 19 [Supll 2]: ii1-ii47.
50. Anemia management in chronic kidney disease. National clinical guideline for management in adults and children. NICE clinical guidelines. 2006.
51. Hsu C-Y, McCulloch C.E., Curhan G.C. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: result from the Third national Health and nutrition Examination Survey. Journal of the American Society of Nephrology 2002; 13: 504-510.
Review
For citations:
Martynov S.A. Klinicheskie i patofiziologicheskie osobennosti anemii pri diabeticheskoy nefropatii. Diabetes mellitus. 2008;11(2):16-22. (In Russ.) https://doi.org/10.14341/2072-0351-5753
Views:
914
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
